on Bausch Health Companies Inc. (NASDAQ:BHC)
Bausch Health Considers Potential Sale of Bausch + Lomb
Bausch Health Companies Inc., a global pharmaceutical company, has confirmed it is exploring a possible sale of its subsidiary, Bausch + Lomb. This consideration follows the strategic decision by Bausch Health's Board of Directors to complete the full separation of its eye health division. As of now, this remains one of several options under review, with no definitive transaction decided.
The Canadian Investment Regulatory Organization (CIRO) requested that Bausch Health validate the potential sales process amid market speculation and stock volatility. The company has stated it will not provide further information until appropriate, highlighting the uncertainty surrounding any potential transaction.
Bausch Health continues to be publicly traded on both the New York Stock Exchange and Toronto Stock Exchange. The company emphasizes that these plans are part of ongoing efforts to optimize their strategic operations and overall business model.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Bausch Health Companies Inc. news